A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare Pharmaceuticals Inc.
- 10 Jun 2017 Biomarkers information updated
- 29 Nov 2012 Planned end date changed from 1 Aug 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 17 Jul 2012 Planned End Date changed from 1 Jul 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History